The ECD, which won CE Mark approval in the European Union last year and is on the market in Canada and Australia, is slated to hit the U.S. market within 30 to 45 days, Advanced Cooling Therapy said.
The device is designed to control patient temperature using a triple-lumen system inserted into the esophagus.
“ACT pioneered the field of core temperature management through the esophagus. With this regulatory milestone, we are looking forward to bringing the ECD to the U.S., offering advanced patient temperature management in an efficient, easy-to-use device that can be quickly placed by a range of healthcare providers in the ER, OR and ICU,” co-founder & president Dr. Erik Kulstad said in prepared remarks. “Our feedback from clinicians in Canada, Europe, and Australia using the ECD to both cool and warm patients has been impressive, and we anticipate strong adoption in the U.S.”
Advanced Cooling Therapy brought in a $1.5 million funding round last August.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.